Search for Clinical Trial Results
Intraocular Lymphoma - 18 Studies Found
| Status | Study |
| Recruiting |
Study Name: Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma Condition:
Date: 2012-02-27 Interventions:
|
| Active, not recruiting |
Study Name: Study of Ibrutinib in Patients With Relapsed or Refractory Primary Central Nervous Lymphoma or Intraocular Lymphoma Condition:
Interventions: Drug: Ibrutinib p.o. 560 mg once a day (four 140 mg capsules) for one year (12 cycles of 28 days) |
| Completed |
Study Name: A Safety Study of Rituximab Plus MTX Injected Into the Cerebrospinal Fluid in the Treatment of Brain Lymphoma Condition:
Date: 2005-09-14 Interventions: Drug: Intraventricular Rituximab Plus MTX Intraventricular |
| Suspended |
Study Name: Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma or Newly Diagnosed or Relapsed or Refractory Intraocular Lymphoma Condition:
Interventions: |
| Withdrawn |
Study Name: Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma Condition:
|
| Completed |
Study Name: Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma Condition:
|
| Active, not recruiting |
Study Name: Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma Condition:
Interventions: |
| Completed |
Study Name: Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma Condition:
|
| Completed |
Study Name: 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas Condition:
|
| Terminated |
Study Name: CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma Condition:
Interventions: |